Greccas (Ticagrelor)

Greccas is indicated for patients who need antiplatelet therapy to lower the chance of thrombotic complications. It is commonly prescribed in the following clinical situations:

• Prevention of thrombotic events in individuals with acute coronary syndrome (ACS).
• Reduction of cardiovascular death, myocardial infarction, and stroke risk after an ACS event.
• Use as part of dual antiplatelet therapy following percutaneous coronary intervention (PCI).
• Management of patients with a high risk of recurrent ischemic events.
• Adjunct therapy in selected patients with stable coronary artery disease when advised by a physician.

Ticagrelor, the active component of Greccas, may cause a range of side effects. These are generally categorized by frequency and severity.

Common

• Shortness of breath or dyspnea, often mild to moderate.
• Headache, which may be intermittent.
• Nausea or gastrointestinal discomfort.
• Minor bruising or bleeding from cuts.
• Dizziness, especially when standing quickly.

Serious

• Severe or uncontrolled bleeding, including intracranial hemorrhage.
• Allergic reactions such as rash, itching, or swelling.
• Liver enzyme elevations indicating possible hepatic injury.
• Thrombotic thrombocytopenic purpura (TTP) in rare cases.
• Sudden drop in blood pressure (hypotension).

Before starting Greccas, certain health considerations should be reviewed with a healthcare professional. Important precautions include:

• History of active bleeding, recent surgery, or hemorrhagic stroke.
• Severe liver impairment or elevated liver enzymes.
• Concomitant use of strong CYP3A inhibitors or inducers.
• Known hypersensitivity to ticagrelor or any excipients.
• Pregnancy, breastfeeding, or planning to become pregnant.
• Renal dysfunction that may affect drug clearance.
• Monitoring for signs of dyspnea or unexplained shortness of breath.

Greccas can interact with other medicines, affecting its safety and effectiveness. Interactions are grouped by the level of risk.

Avoid

• Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.
• Anticoagulants like warfarin or direct oral anticoagulants without dose adjustment.

Use with caution

• CYP3A4 inducers (e.g., rifampin, carbamazepine) that may lower ticagrelor levels.
• Other antiplatelet agents (e.g., aspirin, clopidogrel) when combined therapy is required.
• Proton pump inhibitors that may affect absorption.
• Herbal supplements such as St. John’s wort that influence CYP enzymes.